Increased oxidative stress and apoptosis have been implicated in the cardiotoxicity that
limits the clinical use of cisplatin as an anti-tumoral drug. Our study was conducted to …

This study has been initiated to investigate whether endogenous carnitine depletion and/or
carnitine deficiency is a risk factor during development of cisplatin (CDDP)-induced …

The objective of this study was to evaluate the cardiac toxicity induced by carboplatin, a
second generation platinum-containing anti-cancer drug, and to test whether pravastatin can …

Objective: Cisplatin (CDDP) has been known to be an effective antineoplastic drug;
however, it has a cardiotoxic effect. Curcumin (CMN) and beta-carotene (BC) have been …

Objective: Cisplatin is an anticancer drug used for treating childhood solid tumors.
Symptoms related to cisplatin-induced cardiovascular adverse effects may be mild or …

Despite the clinical reports, few studies have focused on reducing the cardiotoxicity of
cisplatin. In the present study, cardiotoxicity was examined after a single ip injection of …

The higher incidence of cardiotoxicity of doxorubicin (DOX)/paclitaxel (PTX) combination
compared with DOX alone remains to be a major obstacle against effective …

Oxidative stress and apoptosis serve an essential role in cisplatin‑induced cardiotoxicity,
which limits its clinical use, and increases the risk of cardiovascular disease. As a natural …

Background The importance of doxorubicin (Dox), as a potent antitumor antibiotic, is limited
by the development of life-threatening cardiomyopathy. It has been shown that free radicals …

Cisplatin (CP) is used to treat a wide range of tumors and kills cells (anti-neoplastic drug)
through different mechanisms, including, formation of reactive oxygen species (ROS), DNA …